DW

PTO/SB/21 (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995	no persons are required to respond to a confidence Application Number	ollection of information unless it displays a valid OMB control number.			
TO PE TRANSMITTAL	Filing Date	December 31, 2003			
8 FOR	First Named Inventor	Mathiesen, facob			
SEP 2 9 2006 2) FORW	Art Unit	3767			
<i>\$</i> /	Examiner Name				
(to be use 3/ all correspondence after initial	filing) Attorney Docket Number	Gray, Phillip A.			
Total Number of Pages in This Submission	7 Attorney bocket Number	GTI-5001-CP			
	ENCLOSURES (Check al	l that apply)			
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocatic Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s)	Address Status Letter Other Enclosure(s) (please Identify below): * Supp Transmittal (1 page) * Supp IDS Statement (2 pages) * Supp SB/08 Form (1 page)			
Certified Copy of Priority	Landscape Table on C	* Reference (1 item) * Return Postcard (1 item)			
Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks				
SIGNA	TURE OF APPLICANT, ATTO	PRNEY, OR AGENT			
Firm Name BioTechnology Law Group	p ,				
المراحز فيتناهى والمرافعة فعلي المرافع والمرافع والمرافع والمرافع والمرافع والمرافع والمرافع والمرافع والمرافع	andie				
Printed name Daniel M. Chambers					
Date Supromber S	Ne 2006 Co	Reg. No. 34,561			
CERTIFICATE OF TRANSMISSION/MAILING					
sufficient postage as first class mail in an entitle date shown below:	I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:				
Signature UMING X	1) June -	··· ···			
Typed or printed name Daniel M. Chamb	pers	Date Spanish 36,300			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Mathiesen, Iacob

Examiner:

Gray, Phillip A

Serial No.:

10/748,658

Group Art Unit:

3767

Filed:

December 31, 2003

Docket:

GTI-5001-CP

Title:

Electroporation Device and Injection Apparatus

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (1)

Mail Stop: AMENDMENT Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir/Madam:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed material is brought to the attention of the Examiner for consideration in connection with the above-identified patent application.

Applicants respectfully request that the enclosed Supplemental Information Disclosure Statement be entered, and the documents listed on the attached Form SB08A be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the SB08A form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

CERTIFICATE OF MAILING PURSUANT TO 37 CFR § 1.8:

The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop: AMENDMENT, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Name

Daniel M Chambers

Danier M. Champers

Signature

Data

Also, Applicants respectfully request that in patent application USSN 10/612,304, filed July 3, 2003, the Information Disclosure Statement, filed January 8, 2004, be incorporated and considered as part of the present application. As provided in 37 C.F.R. §1.98(d), copies of the documents listed the Information Disclosure Statement, except for EP 0460650, herein attached, are not being provided since they were previously cited by or submitted to the Patent Office in USSN. 10/612,304.

The listed document is being submitted in compliance with 37 CFR § 1.97(b), before the mailing date of the first office action on the merits.

If any fees are due, please contact the undersigned attorney at (858) 350-9690.

The Examiner is invited to contact the Applicants' Representative at (858) 350-9690 if there are any questions regarding this communication.

Respectfully submitted

BioTechnology Law Group 527 N. Highway 101, Suite E Solana Beach, CA 92075-1173

Telephone: 858 350-9690 Facsimile: 858 350-9691

dan@biotechnologylawgroup.com

Daniel M. Chambers Reg. No. 34,561 Substitute for form 1449APTO
INFORMATION DISCLOSURE
STATEMENT BY ARPEICANT
(Use as many sheets as recessary)

SEP 2 2 2005
Sheet 1 of 1

Application Number	10/748,658
Filing Date	December 31, 2003
First Named Inventor	Mathiesen, Iacob
Group Art Unit	3767
Examiner Name	Gray, Phillip A

Examiner Initials *	Cite No.1	USP Document Number	Issued Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines,Where Relevant Passages or Relevant Figures Appear
	A1.	4,882,127	21 Nov 1989	Rosenthal et al	
	A2.	4,341,735	27 Jul 1982	Seifried	
	A3.	3,645,692	29 Feb 1972	Stork et al	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines, Where Relevant Passages or Relevant Figures Appear	T²
	A4.	WO 98/43702	08 Oct 1998	Mathiesen, Iacob		
	A5.	WO 96/39226 A	12 Dec 1996	Genetronics, Inc.		
	A6.	WO 83/04309	12 Aug 1983	Ackermann et al		
	A7.	EP 0693951 B1	26 Aug 1998	Centre National De La Recherche Scientifique		
	A8.	EP 0460650 A3	12 Nov 1991	Labsystems OY		

	OTHE	ER DOCUMENTS NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the include (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publication (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publication (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publication (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publication (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publication (book, magazine, journal, serial, symposium, catalog, etc.), and the article (book, magazine, journal, serial, symposium, catalog, etc.), and the article (book, magazine, journal, serial, symposium, catalog, etc.), and the article (book, magazine, journal, serial, symposium, catalog, etc.), and the article (book, magazine, journal, serial, symposium, catalog, etc.), and the article (book, magazine, journal, symposium, catalog, etc.), and the article (book, magazine, journal, symposium, catalog, etc.), and the article (book, magazine, journal, symposium, catalog, etc.), and the article (book, magazine, journal, symposium, catalog, etc.), and the article (book, magazine, journal, symposium, catalog, etc.),			
	A9.	Chastain, M. et al., "Antigen levels and antibody titers after DNA vaccination," Journal of Pharmaceutical Science 90(4):474-484 (2001)		
	A10.	Sanes, J. R., et al., "Selective expression of an acetylcholine receptor-lacZ transgene in synaptic nuclei of adult muscle fibers," <i>Development</i> 113:1181-1191 (1991)		
			-	

EXAMINE	/Phillip Gray/	DATE CONSIDERED	03/27/2009